Merops Switch to
Inhibitors

Peptidase

Family Clan SEARCHES BLAST
MEROPS SUBMISSIONS

Other
information

Literature for peptidase S01.231: urokinase-type plasminogen activator

Summary Gene structure Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates Pharma

(References are filtered for relevance to Inhibitor. To remove the filter click here. See explanation.)

    2023
  1. Mazzocato,Y., Perin,S., Morales-Sanfrutos,J., Romanyuk,Z., Pluda,S., Acquasaliente,L., Borsato,G., De Filippis,V., Scarso,A. and Angelini,A.
    A novel genetically-encoded bicyclic peptide inhibitor of human urokinase-type plasminogen activator with better cross-reactivity toward the murine orthologue
    Bioorg Med Chem95, 117499-117499. PubMed  Europe PubMed DOI  I
    2. 2022
  2. Zhou,Y., Wu,J., Xue,G., Li,J., Jiang,L. and Huang,M.
    Structural study of the uPA-nafamostat complex reveals a covalent inhibitory mechanism of nafamostat
    Biophys J121, 3940-3949. PubMed  Europe PubMed DOI  I
    3. 2020
  3. Brunet,J.G., Sharma,T., Tasneem,S., Liang,M., Wilson,M.D., Rivard,G.E. and Hayward,C.P.M.
    Thrombin generation abnormalities in Quebec platelet disorder
    Int J Lab Hematole13302-e13302. PubMed  Europe PubMed DOI  I
  4. Joossen,C., Baan,A., Moreno-Cinos,C., Joossens,J., Cools,N., Lanckacker,E., Moons,L., Lemmens,K., Lambeir,A.M., Fransen,E., Delputte,P., Caljon,G., Van der Veken,P., Maes,L., De Meester,I., Kiekens,F., Augustyns,K. and Cos,P.
    A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation
    Sci Rep10, 17268-17268. PubMed  Europe PubMed DOI  I
    5. 2019
  5. Buckley,B.J., Majed,H., Aboelela,A., Minaei,E., Jiang,L., Fildes,K., Cheung,C.Y., Johnson,D., Bachovchin,D., Cook,G.M., Huang,M., Ranson,M. and Kelso,M.J.
    6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease
    Bioorg Med Chem Lett126753-126753. PubMed  Europe PubMed DOI  S  I
  6. Li,C.Y., de Veer,S.J., Law,R.H.P., Whisstock,J.C., Craik,D.J. and Swedberg,J.E.
    Characterising the subsite specificity of urokinase-type plasminogen activator and tissue-type plasminogen activator using a sequence-defined peptide aldehyde library
    Chembiochem20, 46-50. PubMed  Europe PubMed DOI  P  I
  7. Wang,D., Yang,Y., Jiang,L., Wang,Y., Li,J., Andreasen,P.A., Chen,Z., Huang,M. and Xu,P.
    Suppression of tumor growth and metastases by targeted intervention in urokinase activity with cyclic peptides
    J Med Chem62, 2172-2183. PubMed  Europe PubMed DOI  I
  8. Wu,G., Mazzitelli,B.A., Quek,A.J., Veldman,M.J., Conroy,P.J., Caradoc-Davies,T.T., Ooms,L.M., Tuck,K.L., Schoenecker,J.G., Whisstock,J.C. and Law,R.H.P.
    Tranexamic acid is an active site inhibitor of urokinase plasminogen activator
    Blood Adv3, 729-733. PubMed  Europe PubMed DOI  I
    9. 2018
  9. Buckley,B.J., Aboelela,A., Minaei,E., Jiang,L.X., Xu,Z., Ali,U., Fildes,K., Cheung,C.Y., Cook,S.M., Johnson,D.C., Bachovchin,D.A., Cook,G.M., Apte,M., Huang,M., Ranson,M. and Kelso,M.J.
    6-Substituted hexamethylene amiloride (HMA) derivatives as potent and selective inhibitors of the human urokinase plasminogen activator for use in cancer
    J Med Chem61, 8299-8320. PubMed  Europe PubMed DOI  I
  10. Islam,I., Yuan,S., West,C.W., Adler,M., Bothe,U., Bryant,J., Chang,Z., Chu,K., Emayan,K., Gualtieri,G., Ho,E., Light,D., Mallari,C., Morser,J., Phillips,G., Schaefer,C., Sukovich,D., Whitlow,M., Chen,D. and Buckman,B.O.
    Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis
    Bioorg Med Chem Lett28, 3372-3375. PubMed  Europe PubMed DOI  I
  11. Solis-Calero,C., Zanatta,G., Pessoa,C.D.O., Carvalho,H.F. and Freire,V.N.
    Explaining urokinase type plasminogen activator inhibition by amino-5-hydroxybenzimidazole and two naphthamidine-based compounds through quantum biochemistry
    Phys Chem Chem Phys20, 22818-22830. PubMed  Europe PubMed DOI  I
    12. 2017
  12. Xue,G., Gong,L., Yuan,C., Xu,M., Wang,X., Jiang,L. and Huang,M.
    A structural mechanism of flavonoids in inhibiting serine proteases
    Food Funct8, 2437-2443. PubMed  Europe PubMed DOI  S  I
    13. 2016
  13. Jiang,L., Andersen,L.M., Andreasen,P.A., Chen,L. and Huang,M.
    Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate
    Biochim Biophys Acta1860, 599-606. PubMed  Europe PubMed DOI  S  I
    14. 2015
  14. Beloglazova,I.B., Plekhanova,O.S., Katkova,E.V., Rysenkova,K.D., Stambol'skii,D.V., Sulimov,V.B. and Tkachuk,V.A.
    Molecular modeling as a new approach to the development of urokinase inhibitors
    Bull Exp Biol Med158, 700-704. PubMed  Europe PubMed DOI  I
  15. Gladysz,R., Adriaenssens,Y., De Winter,H., Joossens,J., Lambeir,A.M., Augustyns,K. and Van der Veken,P.
    Discovery and SAR of novel and selective inhibitors of urokinase plasminogen activator (uPA) with an imidazo[1,2-a]pyridine scaffold
    J Med Chem58, 9238-9257. PubMed  Europe PubMed DOI  I
  16. Jiang,L., Zhao,B., Xu,P., Sorensen,H.P., Jensen,J.K., Christensen,A., Hosseini,M., Nielsen,N.C., Jensen,K.J., Andreasen,P.A. and Huang,M.
    Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues
    Int J Biochem Cell Biol62, 88-92. PubMed  Europe PubMed DOI  I
  17. Sorensen,H.P., Xu,P., Jiang,L., Kromann-Hansen,T., Jensen,K.J., Huang,M. and Andreasen,P.A.
    Selection of high-affinity peptidic serine protease inhibitors with increased binding entropy from a back-flip library of peptide-protease fusions
    J Mol Biol427, 3110-3122. PubMed  Europe PubMed DOI  I
    18. 2014
  18. Sulimov,V.B., Katkova,E.V., Oferkin,I.V., Sulimov,A.V., Romanov,A.N., Roschin,A.I., Beloglazova,I.B., Plekhanova,O.S., Tkachuk,V.A. and Sadovnichiy,V.A.
    Application of molecular modeling to urokinase inhibitors development
    Biomed Res Int2014, 625176-625176. PubMed  Europe PubMed DOI  I
  19. Zhao,B., Xu,P., Jiang,L., Paaske,B., Kromann-Hansen,T., Jensen,J.K., Sorensen,H.P., Liu,Z., Nielsen,J.T., Christensen,A., Hosseini,M., Sorensen,K.K., Nielsen,N.C., Jensen,K.J., Huang,M. and Andreasen,P.A.
    A cyclic peptidic serine protease inhibitor: increasing affinity by increasing peptide flexibility
    PLoS ONE9, e115872-e115872. PubMed  Europe PubMed DOI  S  I
    20. 2013
  20. Chen,S., Gfeller,D., Buth,S.A., Michielin,O., Leiman,P.G. and Heinis,C.
    Improving binding affinity and stability of peptide ligands by substituting glycines with d-amino acids
    Chembiochem14, 1316-1322. PubMed  Europe PubMed DOI  I
  21. Fasoli,E., Reyes,Y.R., Guzman,O.M., Rosado,A., Cruz,V.R., Borges,A., Martinez,E. and Bansal,V.
    Para-aminobenzamidine linked regenerated cellulose membranes for plasminogen activator purification: Effect of spacer arm length and ligand density
    J Chromatogr B Analyt Technol Biomed Life Sci930, 13-21. PubMed  Europe PubMed DOI  I
  22. Ichimura,A., Matsumoto,S., Suzuki,S., Dan,T., Yamaki,S., Sato,Y., Kiyomoto,H., Ishii,N., Okada,K., Matsuo,O., Hou,F.F., Vaughan,D.E., van Ypersele de Strihou,C. and Miyata,T.
    A small molecule inhibitor to plasminogen activator inhibitor 1 inhibits macrophage migration
    Arterioscler Thromb Vasc Biol33, 935-942. PubMed  Europe PubMed DOI  I
  23. Roodbeen,R., Paaske,B., Jiang,L., Jensen,J.K., Christensen,A., Nielsen,J.T., Huang,M., Mulder,F.A., Nielsen,N.C., Andreasen,P.A. and Jensen,K.J.
    Bicyclic peptide inhibitor of urokinase-type plasminogen activator: mode of action
    Chembiochem14, 2179-2188. PubMed  Europe PubMed DOI  I
    24. 2012
  24. Bhongade,B.A., Amnerkar,N.D., Talath,S., Bhusari,K.P. and Gadad,A.K.
    3D-QSAR studies on isocoumarin-based urokinase-type plasminogen activator (uPA) inhibitors employing linear and non-linear regression analysis methods
    Lett Drug Des Discov9, 874-880.  I
  25. Botkjaer,K.A., Deryugina,E.I., Dupont,D.M., Gardsvoll,H., Bekes,E.M., Thuesen,C.K., Chen,Z., Ploug,M., Quigley,J.P. and Andreasen,P.A.
    Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism
    Mol Cancer Res10, 1532-1543. PubMed  Europe PubMed DOI  I
  26. Liu,Z., Kromann-Hansen,T., Lund,I.K., Hosseini,M., Jensen,K.J., Hoyer-Hansen,G., Andreasen,P.A. and Sorensen,H.P.
    Interconversion of active and inactive conformations of urokinase-type plasminogen activator
    Biochemistry51, 7804-7811. PubMed  Europe PubMed DOI  I
  27. Massey,A.P., Harley,W.R., Pasupuleti,N., Gorin,F.A. and Nantz,M.H.
    2-Amidino analogs of glycine-amiloride conjugates: inhibitors of urokinase-type plasminogen activator
    Bioorg Med Chem Lett22, 2635-2639. PubMed  Europe PubMed DOI  I
  28. Venkatraj,M., Messagie,J., Joossens,J., Lambeir,A.M., Haemers,A., Van der Veken,P. and Augustyns,K.
    Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA)
    Bioorg Med Chem20, 1557-1568. PubMed  Europe PubMed DOI  I
    29. 2011
  29. Hosseini,M., Jiang,L., Sorensen,H.P., Jensen,J.K., Christensen,A., Fogh,S., Yuan,C., Andersen,L.M., Huang,M., Andreasen,P.A. and Jensen,K.J.
    Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors using non-natural arginine analogs
    Mol Pharmacol80, 585-597. PubMed  Europe PubMed DOI  I
  30. Liu,J., Wang,Y., Yang,Y., Jiang,X., Zhao,M., Wang,W., Wu,G., Wu,J., Zheng,M. and Peng,S.
    Pyrolo[1,2:4,5]-1,4-dioxopyrazino[1,2:1,6]pyrido[3,4-b]indoles: a group of urokinase inhibitors, their synthesis, and stereochemistry-dependent activity
    ChemMedChem6, 2312-2322. PubMed  Europe PubMed DOI  I
  31. Mei,S., Liu,J., Zhao,M., Wang,W., Wang,Y., Wu,G., Zheng,M. and Peng,S.
    From Cerius2 based stereoview to mouse and enzyme: the model systems for discovery of novel urokinase inhibitors
    Mol Biosyst7, 2664-2669. PubMed  Europe PubMed DOI  I
    32. 2010
  32. David,H.N., Haelewyn,B., Risso,J.J., Colloc'h,N. and Abraini,J.H.
    Xenon is an inhibitor of tissue-plasminogen activator: adverse and beneficial effects in a rat model of thromboembolic stroke
    J Cereb Blood Flow Metab30, 718-728. PubMed  Europe PubMed DOI  I
  33. Henneke,I., Greschus,S., Savai,R., Korfei,M., Markart,P., Mahavadi,P., Schermuly,R.T., Wygrecka,M., Sturzebecher,J., Seeger,W., Gunther,A. and Ruppert,C.
    Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model
    Am J Respir Crit Care Med181, 611-619. PubMed  Europe PubMed DOI  I
    34. 2009
  34. Jiang,L.G., Zhao,G.X., Bian,C.B., Yuan,C., Huang,Z.X. and Huang,M.D.
    Crystal structures of urokinase-type plasminogen activator in complex with 4-(aminomethyl)benzoic acid and 4-(aminomethyl-phenyl)-methanol
    Jiegou Huaxue28, 253-259.  S  I
  35. Karthikeyan,C., Moorthy,N.S. and Trivedi,P.
    QSAR study of substituted 2-pyridinyl guanidines as selective urokinase-type plasminogen activator (uPA) inhibitors
    J Enzyme Inhib Med Chem24, 6-13. PubMed  Europe PubMed DOI  I
  36. West,C.W., Adler,M., Arnaiz,D., Chen,D., Chu,K., Gualtieri,G., Ho,E., Huwe,C., Light,D., Phillips,G., Pulk,R., Sukovich,D., Whitlow,M., Yuan,S. and Bryant,J.
    Identification of orally bioavailable, non-amidine inhibitors of urokinase plasminogen activator (uPA)
    Bioorg Med Chem Lett19, 5712-5715. PubMed  Europe PubMed DOI  I
    37. 2008
  37. Andersen,L.M., Wind,T., Hansen,H.D. and Andreasen,P.A.
    A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue
    Biochem J412, 447-457. PubMed  Europe PubMed DOI  I
  38. Frederickson,M., Callaghan,O., Chessari,G., Congreve,M., Cowan,S.R., Matthews,J.E., McMenamin,R., Smith,D.M., Vinkovic,M. and Wallis,N.G.
    Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator
    J Med Chem51, 183-186. PubMed  Europe PubMed DOI  I
    39. 2007
  39. Fish,P.V., Barber,C.G., Brown,D.G., Butt,R., Collis,M.G., Dickinson,R.P., Henry,B.T., Horne,V.A., Huggins,J.P., King,E., O'Gara,M., McCleverty,D., McIntosh,F., Phillips,C. and Webster,R.
    Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-Sulfonamidoisoquinolinyl)guanidines
    J Med Chem50, 2341-2351. PubMed  Europe PubMed DOI  I
  40. Grzywa,R., Dyguda-Kazimierowicz,E., Sienczyk,M., Feliks,M., Sokalski,W.A. and Oleksyszyn,J.
    The molecular basis of urokinase inhibition: from the nonempirical analysis of intermolecular interactions to the prediction of binding affinity
    J Mol Model13, 677-683. PubMed  Europe PubMed DOI  I
  41. Joossens,J., Ali,O.M., El-Sayed,I., Surpateanu,G., Van der Veken,P., Lambeir,A.M., Setyono-Han,B., Foekens,J.A., Schneider,A., Schmalix,W., Haemers,A. and Augustyns,K.
    Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties
    J Med Chem50, 6638-6646. PubMed  Europe PubMed DOI  I
  42. [YEAR:29-1-2007]Killeen,S.D., Andrews,E.J., Wang,J.H., Wu,T., Schmalix,W., Muehlenweg,B. and Redmond,H.P.
    Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor, WXC-340, ameliorates endotoxin and surgery-accelerated growth of murine metastases
    Br J Cancer96, 262-268. PubMed  Europe PubMed DOI  I
  43. Zhao,G., Yuan,C., Wind,T., Huang,Z., Andreasen,P.A. and Huang,M.
    Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1
    J Struct Biol160, 1-10. PubMed  Europe PubMed DOI  S  I
    44. 2006
  44. [YEAR:8-2-2006]Heynekamp,J.J., Hunsaker,L.A., Vander Jagt,T.A., Deck,L.M. and Vander Jagt,D.L.
    Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator
    BMC Chem Biol6, 1-1. PubMed  Europe PubMed DOI  I
  45. [YEAR:21-9-2006]Joossens,J., Van der Veken,P., Surpateanu,G., Lambeir,A.M., El-Sayed,I., Ali,O.M., Augustyns,K. and Haemers,A.
    Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position
    J Med Chem49, 5785-5793. PubMed  Europe PubMed DOI  I
  46. [YEAR:17-3-2006]Sienczyk,M. and Oleksyszyn,J.
    Inhibition of trypsin and urokinase by Cbz-amino(4-guanidinophenyl)methanephosphonate aromatic ester derivatives: The influence of the ester group on their biological activity
    Bioorg Med Chem Lett16, 2886-2890. PubMed  Europe PubMed DOI  I
    47. 2005
  47. Bruncko,M., McClellan,W.J., Wendt,M.D., Sauer,D.R., Geyer,A., Dalton,C.R., Kaminski,M.A., Weitzberg,M., Gong,J., Dellaria,J.F., Mantei,R., Zhao,X., Nienaber,V.L., Stewart,K., Klinghofer,V., Bouska,J., Rockway,T.W. and Giranda,V.L.
    Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties
    Bioorg Med Chem Lett15, 93-98. PubMed  Europe PubMed DOI  I
  48. Hansen,M., Wind,T., Blouse,G.E., Christensen,A., Petersen,H.H., Kjelgaard,S., Mathiasen,L., Holtet,T.L. and Andreasen,P.A.
    A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition
    J Biol Chem280, 38424-38437. PubMed  Europe PubMed DOI  I
  49. [YEAR:12-11-2005]Katsuta,Y., Yoshida,Y., Kawai,E., Suetsugu,M., Kohno,Y., Inomata,S. and Kitamura,K.
    trans-4-(Aminomethyl)cyclohexane carboxylic acid methylamide (t-AMCHA methylamide) inhibits the physical interaction between urokinase-type plasminogen activator and stratum corneum, and accelerates the recovery of barrier function
    J Dermatol Sci40, 218-220. PubMed  Europe PubMed DOI  I
  50. Setyono-Han,B., Sturzebecher,J., Schmalix,W.A., Muehlenweg,B., Sieuwerts,A.M., Timmermans,M., Magdolen,V., Schmitt,M., Klijn,J.G. and Foekens,J.A.
    Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1
    Thromb Haemost93, 779-786. PubMed  Europe PubMed DOI  I
    51. 2004
  51. [YEAR:21-6-2004]Barber,C.G., Dickinson,R.P. and Fish,P.V.
    Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines
    Bioorg Med Chem Lett14, 3227-3230. PubMed  Europe PubMed DOI  I
  52. [YEAR:6-5-2004]Joossens,J., Van der Veken,P., Lambeir,A.M., Augustyns,K. and Haemers,A.
    Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator
    J Med Chem47, 2411-2413. PubMed  Europe PubMed DOI  I
  53. [YEAR:19-11-2004]Katz,B.A., Luong,C., Ho,J.D., Somoza,J.R., Gjerstad,E., Tang,J., Williams,S.R., Verner,E., Mackman,R.L., Young,W.B., Sprengeler,P.A., Chan,H., Mortara,K., Janc,J.W. and McGrath,M.E.
    Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA)
    J Mol Biol344, 527-547. PubMed  Europe PubMed DOI  I
  54. [YEAR:18-5-2004]Schweinitz,A., Steinmetzer,T., Banke,I.J., Arlt,M.J., Sturzebecher,A., Schuster,O., Geissler,A., Giersiefen,H., Zeslawska,E., Jacob,U., Kruger,A. and Sturzebecher,J.
    Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents
    J Biol Chem279, 33613-33622. PubMed  Europe PubMed DOI  I
  55. [YEAR:15-1-2004]Wendt,M.D., Rockway,T.W., Geyer,A., McClellan,W., Weitzberg,M., Zhao,X., Mantei,R., Nienaber,V.L., Stewart,K., Klinghofer,V. and Giranda,V.L.
    Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution
    J Med Chem47, 303-324. PubMed  Europe PubMed DOI  I
  56. Wendt,M.D., Geyer,A., McClellan,W.J., Rockway,T.W., Weitzberg,M., Zhao,X., Mantei,R., Stewart,K., Nienaber,V., Klinghofer,V. and Giranda,V.L.
    Interaction with the S1 beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine urokinase inhibitors
    Bioorg Med Chem Lett14, 3063-3068. PubMed  Europe PubMed DOI  S  I
    57. 2003
  57. [YEAR:18-4-2003]Zeslawska,E., Jacob,U., Schweinitz,A., Coombs,G., Bode,W. and Madison,E.
    Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors
    J Mol Biol328, 109-118. PubMed  Europe PubMed DOI  S  I
    58. 2002
  58. [YEAR:21-1-2002]Barber,C.G., Dickinson,R.P. and Horne,V.A.
    Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-pyridinylguanidines
    Bioorg Med Chem Lett12, 181-184. PubMed  Europe PubMed DOI  I
  59. [YEAR:21-1-2002]Barber,C.G. and Dickinson,R.P.
    Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 2: (3-substituted-5-halo-2-pyridinyl)guanidines
    Bioorg Med Chem Lett12, 185-187. PubMed  Europe PubMed DOI  I
  60. [YEAR:5-8-2002]Mackman,R.L., Hui,H.C., Breitenbucher,J.G., Katz,B.A., Luong,C., Martelli,A., McGee,D., Radika,K., Sendzik,M., Spencer,J.R., Sprengeler,P.A., Tario,J., Verner,E. and Wang,J.
    2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors
    Bioorg Med Chem Lett12, 2019-2022. PubMed  Europe PubMed DOI  I
  61. [YEAR:5-8-2002]Spencer,J.R., McGee,D., Allen,D., Katz,B.A., Luong,C., Sendzik,M., Squires,N. and Mackman,R.L.
    4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors
    Bioorg Med Chem Lett12, 2023-2026. PubMed  Europe PubMed DOI  I
    62. 2001
  62. [YEAR:7-8-2001]Klinghofer,V., Stewart,K., McGonigal,T., Smith,R., Sarthy,A., Nienaber,V., Butler,C., Dorwin,S., Richardson,P., Weitzberg,M., Wendt,M., Rockway,T., Zhao,X.M., Hulkower,K.I. and Giranda,V.L.
    Species specificity of amidine-based urokinase inhibitors
    Biochemistry40, 9125-9131. PubMed  Europe PubMed DOI  I
  63. [YEAR:4-6-2001]Subasinghe,N.L., Illig,C., Hoffman,J., Rudolph,M.J., Wilson,K.J., Soll,R., Randle,T., Green,D., Lewandowski,F., Zhang,M., Bone,R., Spurlino,J., DesJarlais,R., Deckman,I., Molloy,C.J., Manthey,C., Zhou,Z., Sharp,C., Maguire,D., Crysler,C. and Grasberger,B.
    Structure-based design, synthesis and SAR of a novel series of thiopheneamidine urokinase plasminogen activator inhibitors
    Bioorg Med Chem Lett11, 1379-1382. PubMed  Europe PubMed DOI  I
    64. 2000
  64. Hajduk,P.J., Boyd,S., Nettesheim,D., Nienaber,V., Severin,J., Smith,R., Davidson,D., Rockway,T. and Fesik,S.W.
    Identification of novel inhibitors of urokinase via NMR-based screening
    J Med Chem43, 3862-3866. PubMed  Europe PubMed DOI  I
  65. [YEAR:15-5-2000]Nienaber,V.L., Davidson,D., Edalji,R., Giranda,V.L., Klinghofer,V., Henkin,J., Magdalinos,P., Mantei,R., Merrick,S., Severin,J.M., Smith,R.A., Stewart,K., Walter,K., Wang,J., Wendt,M., Weitzberg,M., Zhao,X. and Rockway,T.
    Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite
    Structure8, 553-563. PubMed  Europe PubMed DOI  I
  66. [YEAR:11-8-2000]Zeslawska,E., Schweinitz,A., Karcher,A., Sondermann,P., Sperl,S., Sturzebecher,J. and Jacob,U.
    Crystals of the urokinase type plasminogen activator variant beta(c)-uPA in complex with small molecule inhibitors open the way towards structure-based drug design
    J Mol Biol301, 465-475. PubMed  Europe PubMed DOI  S  I
    67. 1999
  67. [YEAR:1-11-1999]Sturzebecher,J., Vieweg,H., Steinmetzer,T., Schweinitz,A., Stubbs,M.T., Renatus,M. and Wikstrom,P.
    3-amidinophenylalanine-based inhibitors of urokinase
    Bioorg Med Chem Lett9, 3147-3152. PubMed  Europe PubMed DOI  I
    68. 1984
  68. [YEAR:1-6-1984]Lijnen,H.R., Uytterhoeven,M. and Collen,D.
    Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethylketones
    Thromb Res34, 431-437. PubMed  Europe PubMed  I
    69. 1974
  69. Thorsen,S. and Astrup,T.
    Substrate composition and the effect of úomegaú-aminocaproic acid on tissue plasminogen activator and urokinase-induced fibrinolysis
    Thromb Diath Haemorrh32, 306-324. PubMed  Europe PubMed  I
    70. 1970
  70. Landmann,H. and Markwardt,F.
    [Irreversible synthetic inhibitors of urokinase]
    Experientia26, 145-147. PubMed  Europe PubMed DOI  I

feedback
Page created 8-September-2023

EMBL-EBI logo

© 2025 EBI
Terms of use